Interview with Dr. Damaj highlights Commercial Products for Men's and Women's Health, Recent Company Milestones Achieved, and Long Term Domestic and International Growth Strategy

SAN DIEGO, CA / ACCESSWIRE / November 3, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (INNV) today announced that the interview of Dr. Bassam Damaj, President & Chief Executive Officer of the Company, on Wide World of Stocks was broadcast on Friday October 31, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.

In the interview, Damaj highlighted the milestones achieved by the Company, its growth, the commercial availability of its products, the signed commercial partnerships and expansion into 28 international markets.

"It was a pleasure to present to the viewers of Wide World of Stocks and to continue to provide information about Innovus and our commercial products", said Dr. Damaj.

The interview can be viewed online on the Wide World of Stocks YouTube channel at http://wideworldofstocks.com/.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction and vitality products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of four marketed products in this space including Sensum+(TM) (for sales outside the U.S. only), Zestra(R) Glide and Vesele(R).

For more information, go to www.innovuspharma.com.

INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize its products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Innovus Pharma Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

SOURCE: Innovus Pharmaceuticals, Inc.